Efficacy of folic acid in the treatment of non-alcoholic fatty liver
Phase 3
- Conditions
- onalcoholic steatohepatitis.Fatty (change of) liver, not elsewhere classifiedK75.81
- Registration Number
- IRCT20150819023685N2
- Lead Sponsor
- Ghoum University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Patients who are diagnosed to have non alcoholic fatty liver disease (grade 2 and 3) confirmed with ultrasonography and fibroscan results.
Ages between 18-65 years
Serum alanine transaminase enzyme level higher than 30 U/
Exclusion Criteria
Having diseases such as liver disease and decompensated Cirrhosis
Having diseases such as hereditary hemochromatosis and Wilson's disease
Consumption of statins and hepatotoxic drugs such as calcium channel blocker, methotrexate, amiodarone and chloroquine
Intake of folate, B12, vitamin E and omega-3 supplements during the last 6 months
History of receiving total parenteral nutrition during last 6 months
Pregnancy
Lactation
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method iver stiffness. Timepoint: At baseline and 24 weeks after the start of the intervention. Method of measurement: Fibroscan.
- Secondary Outcome Measures
Name Time Method Blood levels of liver enzymes. Timepoint: At baseline and 24 weeks after the start of the intervention. Method of measurement: Blood test.